Search results
Showing 1 to 6 of 6 results for eptinezumab
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Eptinezumab for preventing cluster headache attacks TSID 12087
Topic prioritisation
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.